D.E. Shaw & Co’s Trillium Therapeutics Inc. TRIL Stock Holding History

D.E. Shaw & Co’s Portfolio TRIL Stock Details TRIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-34,014	Closed	-$597K	–	5919
2021 Q3	$597K	Sell	34,014 -23,022	-40%	-$269K	﹤0.01%	3981
2021 Q2	$553K	Buy	+57,036	New	+$537K	﹤0.01%	3988
2021 Q1	–	Sell	-42,996	Closed	-$632K	–	4645
2020 Q4	$632K	Sell	42,996 -9,137	-18%	-$132K	﹤0.01%	3278
2020 Q3	$741K	Buy	+52,133	New	+$520K	﹤0.01%	3039

Other funds holding TRIL

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

D.E. Shaw & Co's TRIL Position: Q4 2021 in Review

D.E. Shaw & Co sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 34,014 shares — an estimated $597K sold.

D.E. Shaw & Co first reported a position in TRIL in Q3 2020 and held it in 4 quarters. The position peaked at $741K in Q3 2020. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.

D.E. Shaw & Co reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
D.E. Shaw & Co sold 34,014 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $597K.
D.E. Shaw & Co first reported a position in Trillium Therapeutics Inc. in Q3 2020 and held it in 4 quarters.
D.E. Shaw & Co's Trillium Therapeutics Inc. position peaked at $741K in Q3 2020.
2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.

Based on D.E. Shaw & Co's 13F filing for Q4 2021, filed 14 Feb 2022.